Abstract
Objective
To test the activity of a small molecule compound that targets Lipid II against Acinetobacter baumannii.
Methods
Susceptibility to small molecule Lipid II inhibitor BAS00127538 was assessed using carbapenem- and colistin-resistant clinical isolates of A. baumannii. In addition, synergy between colisitin and this compound was assessed.
Results
Small molecule Lipid II inhibitor BAS00127538 potently acts against A. baumannii and acts synergistically with colistin.
Conclusion
For the first time, a compound that targets Lipid II is described that acts against multi-drug resistant isolates of A. baumannii. The synergy with colistin warrants further lead development of BAS00127538.
Keywords:
Acknowledgments
The Laboratory of Pathology, University of Maryland Baltimore School of Medicine is gratefully acknowledged for providing the A. baumannii clinical isolates. This work is supported by the National Institutes of Health grant to the author (Grant R21AI092033).
Disclosure
The author reports no conflicts of interest in this work. US patent applications # 61/656,039 and US Non-Provisional Patent Application # 13/883,564 have been filed (Alexander D MacKerell and Erik PH de Leeuw, Inventors).